148 related articles for article (PubMed ID: 35973802)
41. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
42. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
43. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
[TBL] [Abstract][Full Text] [Related]
44. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
45. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
46. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
47. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
[TBL] [Abstract][Full Text] [Related]
49. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
50. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Harper L; Cockwell P; Adu D; Savage CO
Kidney Int; 2001 May; 59(5):1729-38. PubMed ID: 11318943
[TBL] [Abstract][Full Text] [Related]
51. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
[TBL] [Abstract][Full Text] [Related]
52. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
53. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
[TBL] [Abstract][Full Text] [Related]
54. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.
Puéchal X; Iudici M; Perrodeau E; Bonnotte B; Lifermann F; Le Gallou T; Karras A; Blanchard-Delaunay C; Quéméneur T; Aouba A; Aumaître O; Cottin V; Hamidou M; Ruivard M; Cohen P; Mouthon L; Guillevin L; Ravaud P; Porcher R; Terrier B;
JAMA Netw Open; 2022 Nov; 5(11):e2243799. PubMed ID: 36441554
[TBL] [Abstract][Full Text] [Related]
55. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
56. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Viviano L; Ding L; Sejismundo LP; Mieras K; Iklé D; Jepson B; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Stone JH;
Arthritis Rheum; 2013 Sep; 65(9):2441-9. PubMed ID: 23754238
[TBL] [Abstract][Full Text] [Related]
57. The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study.
Fonseca JA; Gameiro J; Duarte I; Jorge S; Lopes JA
Nefrologia (Engl Ed); 2021; 41(3):321-328. PubMed ID: 36165341
[TBL] [Abstract][Full Text] [Related]
58. Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis.
Berti A; Hillion S; Hummel AM; Son YM; Chriti N; Peikert T; Carmona EM; Abdulahad WH; Heeringa P; Harris KM; St Clair EW; Brunetta P; Fervenza FC; Langford CA; Kallenberg CG; Merkel PA; Monach PA; Seo P; Spiera RF; Stone JH; Grandi G; Sun J; Pers JO; Specks U; Cornec D;
JCI Insight; 2021 Nov; 6(22):. PubMed ID: 34618687
[TBL] [Abstract][Full Text] [Related]
59. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
60. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.
McAdoo SP; Hall A; Levy J; Salama AD; Pusey CD
J Clin Rheumatol; 2012 Oct; 18(7):336-40. PubMed ID: 23047533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
